FDA Adverse Event Injury Summary report: N

TAXUS LIBERTE PACLITAXEL-ELUTING CORONARY STENT SYSTEM

MDR report key: 1833353 · Received September 14, 2010

Report

Report Number
2134265-2010-04215
Event Type
Injury
Date Received
September 14, 2010
Date of Event
November 6, 2009
Report Date
August 23, 2010
Manufacturer
BOSTON SCIENTIFIC - GALWAY
Product Code
NIQ
PMA / PMN Number
P060008
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4).

Additional Manufacturer Narrative · 1

DEVICE IS A COMBINATION PRODUCT. DEVICE EVALUATED BY MANUFACTURER - IT IS INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION; THEREFORE A FAILURE ANALYSIS OF THE COMPLAINT DEVICE COULD NOT BE COMPLETED. A REVIEW OF THE BATCH HISTORY, HISTORICAL TRENDING, AND SIMILAR COMPLAINT TRENDING REVIEW FOR THE PRODUCT FAMILY WILL BE CONDUCTED. IF THERE IS ANY FURTHER RELEVANT INFORMATION FROM THAT REVIEW, A SUPPLEMENTAL MEDWATCH WILL BE FILED. (B)(4)

Description of Event or Problem · 1

(B)(4). IT WAS REPORTED THAT POST A CORONARY STENTING TREATMENT PROCEDURE, THE PATIENT EXPERIENCED RESTENOSIS. THE TARGET LESION BEING TREATED WAS LOCATED IN THE PROXIMAL RIGHT CORONARY ARTERY (RCA). FOLLOW-UP CORONARY ANGIOGRAM WAS PERFORMED. THE LESION WAS 75% STENOSED, 3.00MM IN DIAMETER AND 33.0MM LONG. IN (B)(6) 2009, RESTENOSIS WAS CONFIRMED. A TARGET VESSEL RE-INTERVENTION WAS PERFORMED WITH AN UNKNOWN BALLOON CATHETER AND A NON-BSC STENT. POST PROCEDURE VISUAL INSPECTION REVEALED 0% STENOSIS. THE EVENT WAS CONSIDERED RESOLVED 1 DAY LATER. IN (B)(6) 2010, 1 YEAR FOLLOW-UP WAS PERFORMED AND THE PATIENT HAD NO ANGINAL SYMPTOM. NO PATIENT COMPLICATIONS WERE REPORTED AND THE PATIENT'S STATUS IS GOOD.

Description of Event or Problem · 1

IT WAS FURTHER REPORTED THAT DURING THE INDEX PROCEDURE, A NEW LESION LOCATED IN THE PROXIMAL RIGHT CORONARY ARTERY WAS 90% STENOSED, 3.0MM IN DIAMETER AND 20MM LONG. THE LESION WAS TREATED WITH PLACEMENT OF A 3.0X20MM TAXUS LIBERTE STENT. POST DILATION WAS PERFORMED. RESIDUAL STENOSIS WAS 0% WITH TIMI 3 FLOW NOTED. THE PATIENT WAS DISCHARGED 5 DAYS LATER WITHOUT COMPLICATIONS ON ASPIRIN AND TICLOPIDINE HYDROCHLORIDE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 TAXUS LIBERTE PACLITAXEL-ELUTING CORONARY STENT SYSTEM CORONARY DRUG-ELUTING STENT NIQ BOSTON SCIENTIFIC - GALWAY UNK433

Patients

Seq Age Sex Outcome Treatment
1 64 YR Required Intervention